Sign In
Buy VTRS
$16.39
+0.120 (+0.738%)
At Close: Jul 13, 2026
Viatris Inc. (VTRS) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)
02:03pm, Tuesday, 14'th Jan 2025
Viatris Inc. (NASDAQ:VTRS ) 43rd Annual J.P. Morgan Healthcare Conference 2025 January 14, 2025 11:15 AM ET Company Participants Scott Smith - CEO Doretta Mistras - CFO Philippe Martin - Chief R&D Off
Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06:59am, Tuesday, 07'th Jan 2025
PITTSBURGH , Jan. 7, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference
Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes
01:46pm, Monday, 06'th Jan 2025
We have rated Viatris in the "neutral/hold" category since 2021. Over this time, the stock has lagged Treasury bills, despite sporting a high double digit "free cash flow yield". We tell you why that
US FDA sends warning letter to Viatris over India manufacturing facility
08:12am, Monday, 23'rd Dec 2024
Viatris said on Monday it has received a warning letter from the U.S. Food and Drug Administration after an inspection at its oral finished dose manufacturing facility in Indore, India earlier this ye
Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology
06:59am, Wednesday, 18'th Dec 2024
Biomarker data from CARE study characterizing cenerimod's mechanism of action in systemic lupus erythematosus also published in the Annals of the Rheumatic Diseases PITTSBURGH , Dec. 18, 2024 /PRNewsw
Mapi Pharma is Seeking New Depot Product Partnerships
08:30am, Monday, 02'nd Dec 2024
Management to Participate in 7th Annual Evercore HealthCONx Conference Management to Participate in 7th Annual Evercore HealthCONx Conference
2 Generic Drug Stocks Ready to Surge in 2025
08:30am, Wednesday, 27'th Nov 2024
Generic and biosimilar drugs are often preferred over the brand name version due to their cheaper prices. Generics are exact duplicates of the branded counterparts, while biosimilars are "similar" and
UK watchdog fines Viatris $1.9 mln over rule breach in Theramex probe
05:01am, Friday, 22'nd Nov 2024
Britain's competition watchdog fined U.S. firm Viatris 1.5 million pounds ($1.88 million) on Friday for violating an order during its investigation into Theramex's acquisition of European rights to tw
Viatris Inc. (VTRS) Management Presents at Jefferies London Healthcare Conference (Transcript)
08:59am, Thursday, 21'st Nov 2024
Viatris Inc. (NASDAQ:VTRS ) Jefferies London Healthcare Conference Transcript November 21, 2024 5:30 AM ET Company Participants Scott Smith - Chief Executive Officer Doretta Mistras - Chief Financial
Viatris Inc. (VTRS) UBS Global Healthcare Conference (Transcript)
03:21pm, Friday, 15'th Nov 2024
Viatris Inc. (NASDAQ:VTRS ) UBS Global Healthcare Conference November 12, 2024 11:45 AM ET Company Participants Doretta Mistras - CFO Conference Call Participants Ashwani Verma - UBS Ashwani Verma Goo
Bargain Priced Viatris Reports Strong Q3 Earnings Results
02:36pm, Friday, 08'th Nov 2024
Bargain Priced Viatris Reports Strong Q3 Earnings Results
Generic Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt Paydown
12:39pm, Thursday, 07'th Nov 2024
Viatris Inc. VTRS reported third-quarter 2024 total net sales of $3.74 billion. That's down 5%, beating the consensus of $3.71 billion, but up about 3% on a divestiture-adjusted operational basis c
Viatris Beats on Q3 Earnings and Revenues, Lowers Profit Guidance
12:20pm, Thursday, 07'th Nov 2024
VTRS Q3 earnings and sales beat estimates. New products perform well.
Viatris Inc. (VTRS) Q3 2024 Earnings Call Transcript
10:50am, Thursday, 07'th Nov 2024
Viatris Inc. (NASDAQ:VTRS ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Of
Viatris (VTRS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
10:35am, Thursday, 07'th Nov 2024
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compa
